4.7 Article

Towards better implementation of cancer screening in Europe through improved monitoring and evaluation and greater engagement of cancer registries

Journal

EUROPEAN JOURNAL OF CANCER
Volume 51, Issue 2, Pages 241-251

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2014.10.022

Keywords

Epidemiology; Cancer prevention; Cancer screening; Cancer registration; Evaluation; Monitoring; Quality assurance

Categories

Funding

  1. European Union [LSSH-CT-2008-219453, 219453]
  2. European Cooperation on Development and Implementation of Cancer Screening and Prevention Guidelines (ECCG-ECN) [2006322]

Ask authors/readers for more resources

Proposals to improve implementation, monitoring and evaluation of breast, cervical and colorectal cancer screening programmes have been developed in a European project involving scientists and professionals experienced in cancer registration (EUROCOURSE). They call for a clear and more active role for cancer registries through better interfaces with cancer screening programmes and adapting data contents of cancer registries for evaluation purposes. Cancer registries are recognised as essential for adequate evaluation of cancer screening programmes, but they are not involved in screening evaluation in several European countries. This is a key barrier to improving the effectiveness of programmes across Europe. The variation in Europe in the implementation of cancer screening offers a unique opportunity to learn from best practices in collaboration between cancer registries and screening programmes. Population-based cancer registries have experience and tools in collecting and analysing relevant data, e.g. for diagnostic and therapeutic determinants of mortality. In order to accelerate improvements in cancer control we argue that cancer registries should take co-responsibility in promoting effective screening evaluation in Europe. Additional investments are vital to further development of infrastructures and activities for screening evaluation and monitoring in the national settings and also at the pan-European level. The EUROCOURSE project also aimed to harmonise implementation of the European quality assurance guidelines for cancer screening programmes across Europe through standardising routine data collection and analysis, and definitions for key performance indicators for screening registers. Data linkage between cancer and screening registers and other repositories of demographic data and cause of death and where available clinical registers is key to implementing the European screening standards and thereby reducing the burden of disease through early detection. Greater engagement of cancer registries in this collaborative effort is also essential to develop adequate evaluation of innovations in cancer prevention and care. (C) 2014 The Authors. Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Invitation strategies and coverage in the population-based cancer screening programmes in the European Union

Diama B. Vale, Ahti Anttila, Antonio Ponti, Carlo Senore, Rengaswamy Sankaranaryanan, Guglielmo Ronco, Nereo Segnan, Mariano Tomatis, Maja P. Zakelj, Klara M. Elfstrom, Stefan Lonnberg, Joakim Dinner, Partha Basu

EUROPEAN JOURNAL OF CANCER PREVENTION (2019)

Article Public, Environmental & Occupational Health

The legal framework for European cervical cancer screening programmes

Ondrej Majek, Ahti Anttila, Marc Arbyn, Evert-Ben van Veen, Birgit Engesaeter, Stefan Lonnberg

EUROPEAN JOURNAL OF PUBLIC HEALTH (2019)

Article Oncology

Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991-2010 (Automated Childhood Cancer Information System): a population-based study

Eva Steliarova-Foucher, Miranda M. Fidler, Murielle Colombet, Brigitte Lacour, Peter Kaatsch, Marion Pineros, Isabelle Soerjomataram, Freddie Bray, Jan Willem Coebergh, Rafael Peris-Bonet, Charles A. Stiller

LANCET ONCOLOGY (2018)

Article Gastroenterology & Hepatology

Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report

Carlo Senore, Partha Basu, Ahti Anttila, Antonio Ponti, Mariano Tomatis, Diama Bhadra Vale, Gugliemo Ronco, Isabelle Soerjomataram, Maja Primic-Zakelj, Emilia Riggi, Joakim Dillner, Miriam Klara Elfstrom, Stefan Lonnberg, Rengaswamy Sankaranarayanan, Nereo Segnan

Article Oncology

Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality

A. M. J. Reedijk, K. Klein, J. W. W. Coebergh, L. C. Kremer, A. G. Dinmohamed, V de Haas, A. B. Versluijs, G. J. Ossenkoppele, H. B. Beverloo, R. Pieters, C. M. Zwaan, G. J. L. Kaspers, H. E. Karim-Kos

LEUKEMIA (2019)

Review Oncology

Research driving innovation: what are key factors for successful integration of translational science into oncology care concepts? 5th European Roundtable Meeting (ERTM) May 4th, 2018, Berlin, Germany

Olaf Ortmann, Julie Torode, Chris Harrison, Johannes Bruns, Ulrike Helbig, Nicolas Philippou, Stefan Schreck, Tit Albreht, Josep Borras, Jan-Willem Coebergh, Andreas Hochhaus, Monika Klinkhammer-Schalke, Christoph Kowalski, Margarete Landenberger, Katrin Mugele, Ralf Rambach

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

Letter Respiratory System

International trends in COPD mortality, 1995-2017

Joannie Lortet-Tieulent, Isabelle Soerjomataram, Jose Luis Lopez-Campos, Julio Ancochea, Jan Willem Coebergh, Joan B. Soriano

EUROPEAN RESPIRATORY JOURNAL (2019)

Article Hematology

Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015

Ardine M. J. Reedijk, Eline A. M. Zijtregtop, Jan Willem W. Coebergh, Friederike A. G. Meyer-Wentrup, Konnie M. Hebeda, C. Michel Zwaan, Geert O. R. Janssens, Rob Pieters, Wouter J. Plattel, Avinash G. Dinmohamed, Josee M. Zijlstra, Leontien C. M. Kremer, Pieternella J. Lugtenburg, Auke Beishuizen, Henrike E. Karim-Kos

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Article Oncology

Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma

M. L. Tas, A. M. J. Reedijk, H. E. Karim-Kos, L. C. M. Kremer, C. P. van de Ven, M. P. Dierselhuis, N. K. A. van Eijkelenburg, M. van Grotel, K. C. J. M. Kraal, A. M. L. Peek, J. W. W. Coebergh, G. O. R. Janssens, B. de Keizer, R. R. de Krijger, R. Pieters, G. A. M. Tytgat, M. M. van Noesel

EUROPEAN JOURNAL OF CANCER (2020)

Review Oncology

Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany

O. Ortmann, J. Torode, W. Schmiegel, C. Thomssen, M. Hakama, P. Basu, U. Ringborg, U. Helbig

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)

Article Oncology

Increasing incidence of cancer and stage migration towards advanced disease in children and young adolescents in the Netherlands, 1990-2017

M. J. Reedijk Ardine, Leontien C. Kremer, Otto Visser, Valery Lemmens, Rob Pieters, Jan Willem W. Coebergh, Henrike E. Karim-Kos

EUROPEAN JOURNAL OF CANCER (2020)

Article Oncology

Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015

Ardine M. J. Reedijk, Jan Willem W. Coebergh, Hester A. de Groot-Kruseman, Inge M. van der Sluis, Leontien C. Kremer, Henrike E. Karim-Kos, Rob Pieters

Summary: The epidemiologic progress against childhood and adolescent acute lymphoblastic leukemia in the Netherlands showed stable overall incidence rates, despite increases in certain subtypes in different age groups. The survival rates for patients have improved, while the mortality rates have decreased, primarily due to treatment in pediatric oncology centers.

LEUKEMIA (2021)

Correction Oncology

Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany (vol 146, pg 1813, 2020)

O. Ortmann, J. Torode, W. Schmiegel, C. Thomssen, M. Hakama, P. Basu, U. Ringborg, U. Helbig

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Article Obstetrics & Gynecology

Setting the record straight-Correcting uterine cancer incidence and mortality in the Nordic countries by reallocation of unspecified cases

Veli-Matti Partanen, Sirpa Heinavaara, Ahti Anttila, Jenni Hakkarainen, Stefan Lonnberg

Summary: This study corrected the incidence and mortality figures of cervix and corpus uteri cancers in Nordic countries by reallocating unspecified uterine cancer deaths and cases. The reallocation significantly impacted the number of cases and deaths for both cancers, with Finland being the only country where mortality rate did not substantially increase after reallocation. Efforts to validate cause of death data with incidence data from cancer registries are warranted to avoid erroneous conclusions based on uncorrected cancer burden.

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2022)

Article Oncology

Progress against non-Hodgkin's lymphoma in children and young adolescents in the Netherlands since 1990: Stable incidence, improved survival and lower mortality

Ardine M. J. Reedijk, Auke Beishuizen, Jan Willem W. Coebergh, Bianca A. W. Hoeben, Leontien C. M. Kremer, Konnie M. Hebeda, Rob Pieters, Jan L. C. Loeffen, Henrike E. Karim-Kos

Summary: This population-based epidemiological study in the Netherlands shows significant progress against childhood and young adolescent NHL since 1990. The incidence of NHL has decreased among children aged 5-9, while survival rates have improved and mortality rates have steadily decreased over time.

EUROPEAN JOURNAL OF CANCER (2022)

Article Oncology

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo

Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial

Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi

Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort

Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri

Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Impact of colorectal cancer screening on survival after metachronous metastasis

Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman

Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY)

Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia

Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies

Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study

Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond

Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.

EUROPEAN JOURNAL OF CANCER (2024)

Letter Oncology

Osimertinib-induced urticarial vasculitis in a patient with lung cancer: A rare cutaneous toxicity

Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Deep learning based histological classification of adnex tumors

Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank

Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction

Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen

Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases

Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li

Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Peptide absent sequences emerging in human cancers

Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares

Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.

EUROPEAN JOURNAL OF CANCER (2024)